English 
ニューシグナル・セラピューティクス社., a Tohoku University-based company developing treatments for Alzheimer’s disease, has raised 1.15 billion yen in Series A funding through a third-party allotment of new shares to the following investors: In addition, the company has received a 1.1 billion yen subsidy from AMED’s FY2023 “Drug Discovery Venture Ecosystem Strengthening Project” to support the growth of venture companies engaged in innovative drug discovery development, bringing the total amount raised in this round to 2.25 billion yen.
こちらもお読みください： 順天堂大学と日本IBM、患者の最適な医療機関への転院を支援するPFM AIマッチングシステムの構築・運用に着手
背景
NTX is a startup working to commercialize seeds from Tohoku University. We are working on developing drug candidate compounds to contribute to improving the lives of patients and their families suffering from Alzheimer’s disease, which continues to rapidly increase around the world, through the development of groundbreaking treatments for the disease.
In recent years, new drugs have been introduced that are expected to slow the progression of Alzheimer’s disease, and while expectations are high, there is also much discussion about the difficulty of managing treatment, the high medical costs, and the appropriateness of target patients based on risk-return, etc. We believe that our product under development can be a groundbreaking treatment that solves these issues, and we aim to deliver it to the patients and their families who are eagerly awaiting it.
ソース PRタイムズ
日本語